drugset / Trial / NCT01804244

A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants

NCT01804244

Phase 4 Completed 8 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of TMC278 after a single oral dose of TMC278 25 mg tablet (27.5 mg as the hydrochloride salt) under fed conditions in healthy Japanese adult male participants.

Timeline

Start
2013-03
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilpivirine Small molecule 25 mg Oral

Indications

No indication recorded.